Subjects of the Control and T2DM groups had similar interleukin-6 levels; and interleukin-6 was significantly higher in both tumor groups, compared to all of those observed in control groups (p < 0.0001 CRC vs Control and T2DM, p = 0.0011 CRC + T2DM vs Control, and p = 0.0069 CRC + T2DM vs T2DM; Figure 1b). This evidence concerns the gene IL6 and colorectal carcinoma.